Top 10 CRISPR Stocks to Buy Now

Page 1 of 10

In this article, we will take a look at the Top 10 CRISPR Stocks to Buy Now.

Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address unresolved medical needs. Gene editing and gene therapy are two of the sector’s most pivotal developments, with CRISPR-Cas9 at the forefront. This tool, inspired by the innate defenses of bacteria, functions as precise genetic scissors.

Additionally, the regulatory environment around gene and regenerative therapies has advanced significantly. With the aid of the Regenerative Medicine Advanced Therapy (RMAT) designation, which speeds up review processes and offers extra support for developers, the FDA has established more transparent development routes in the United States. Similarly, Europe has advanced its Advanced Therapy Medicinal Products (ATMP) guidelines.

The market for gene editing in the United States has shown massive growth, reaching $3.19 billion in 2024. Estimates for the future from Precedence Research indicate an even greater rise, with gene editing projected to reach $13.99 billion by 2034 at a compound annual growth rate (CAGR) of 15.93%. Financially and economically, annual spending on gene editing treatments is expected to reach a peak of $25.3 billion in 2026 and then level off at $21 billion by 2034.

Top 10 CRISPR Stocks to Buy Now

Pixabay/Public Domain

Our Methodology

For this list, we first examined companies in the gene-editing industry by utilizing media coverage and ETF holdings. The list was then narrowed by focusing on the best-performing stocks with the greatest number of hedge fund investors, as determined by Insider Monkey’s database of hedge funds as of the end of the first quarter of 2025.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

10. Editas Medicine, Inc. (NASDAQ:EDIT)

Number of Hedge Fund Holders: 10

Editas Medicine, Inc. (NASDAQ:EDIT) ranks among the best CRISPR stocks to buy. At the European Hematology Association 2025 Congress on June 12, Editas Medicine, Inc. (NASDAQ:EDIT) revealed new in vivo data showing notable progress in gene editing for beta thalassemia and sickle cell disease.

According to the study, a single dose of the company’s proprietary targeted lipid nanoparticle (tLNP) in non-human primates exceeded the therapeutic threshold by achieving a mean on-target editing level of 58% in the HBG1/2 promoter region of hematopoietic stem cells. Editas’ position in the gene editing market is strengthened by the result, enhancing the company’s potential to offer a novel treatment for these illnesses with favorable biodistribution and minimal liver targeting.

A clinical-stage biotechnology company, Editas Medicine, Inc. (NASDAQ:EDIT) develops gene-editing treatments that use CRISPR technology to modify patients’ genomes to treat genetic diseases. Editas distinguishes itself from other major biotech companies that are seeking alternative genomic therapeutics by using an “in vivo gene editing upregulation strategy.”

Page 1 of 10